

Partnering with Primary Peptides

Primary Peptides has developed a set of powerful new technologies that enable us to:

- 1. Block the interactions between any arbitrary pair of proteins**
- 2. Acutely and reversibly reduce the level of a particular protein, without interfering with messenger RNA expression, by targeting that protein for proteasomal or lysosomal degradation.**

Primary Peptides scientists have longstanding broad expertise in neuroscience, proteomics and cell signaling, and have already developed lead compounds in the following areas:

Stroke
Heart attack
Parkinson's
Huntington's
Prostate cancer

We are in the lead optimization stage for several other diseases, and have identified therapeutically relevant targets in other indications.

Primary Peptides welcomes collaboration. We are interested in collaboration with both commercial and academic partners. If your project can identify a protein whose levels need to be reduced, we can generally provide a targeting peptide to do so. Similarly, we can work with you to develop blockers of particular protein-protein interactions. If you have identified a biological target for a particular disease or condition, we should be able to rapidly develop a lead compound for that target. If you have a disease application, but have not yet converged on a target, we can provide expertise and assistance at this level as well.

For further information, please contact:

Max Cynader: cynader@brain.ubc.ca (604-649-2274)

Visit our website: www.primarypeptides.com




CORE TECHNOLOGIES

I. Peptide Array (This technology can identify the loci of protein-protein interactions)

-Arrays of defined protein overlapping peptides

- Overlapping sequence design increases sensitivity
- Layer-by-layer direct synthesis
- “Stand-up” immobilization
- Wide choice of labeling, annotations and modifications
- Versatile reagent applications



II. Peptide-mediated Protein Knockdown Technology (Replacing antisense and siRNA)

- A simple, non-virally mediated, cell-membrane-permeant, targeting peptide-based system
- Non-siRNA method, clinically applicable
- Versatile: it can acutely and reversibly knock down ANY protein of interest
- Tested both *in vivo* and *in vitro*

